Product Information
ZARXIO 300 MCG/0.5 ML SYRINGE is a brand biologic product labeled by Sandoz Inc., priced at $531.6550 per ML under NDC 61314031801. Its NADAC has been published 129 times since Apr 17, 2024.
Strength
300 ug/.5mL
Manufacturer
Sandoz Inc.NDC
61314031801
Classification
Brand Biologic
Dosage Form
INJECTION, SOLUTION
Route
INTRAVENOUS; SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
FILGRASTIMApproval Type
Biologic (BLA)
FDA Application
BLA125553On Market Since
3/6/2015
Pharmacological Classes
Price Statistics
The NADAC for ZARXIO 300 MCG/0.5 ML SYRINGE has been published 129 times since Apr 17, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $531.6550 per ML |
|---|---|
| All-time high | $534.3527 (Sep 10, 2025) |
| All-time low | $526.4500 (Aug 21, 2024) |
| 52-week high | $534.2080 |
| 52-week low | $531.6550 |
| Median price | $532.7178 |
| Average price | $531.2914 |
| Largest weekly change | +0.6% (May 21, 2025) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sandoz Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
filgrastim-sndz market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Leukocyte Growth Factor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ZARXIO 300 MCG/0.5 ML SYRINGE?
The current National Average Drug Acquisition Cost (NADAC) for ZARXIO 300 MCG/0.5 ML SYRINGE, manufactured by Sandoz Inc., is $531.6550 per ML (NDC 61314031801), effective Sep 30, 2026.
How has the price of ZARXIO 300 MCG/0.5 ML SYRINGE changed over time?
Over the history we have for it, the NADAC for ZARXIO 300 MCG/0.5 ML SYRINGE has held within roughly two percent of its current level. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for ZARXIO 300 MCG/0.5 ML SYRINGE?
Since Apr 17, 2024, the NADAC for ZARXIO 300 MCG/0.5 ML SYRINGE has ranged from a low of $526.4500 (Aug 21, 2024) to a high of $534.3527 (Sep 10, 2025), with a median of $532.7178 per ML.
Are there cheaper alternatives to ZARXIO 300 MCG/0.5 ML SYRINGE?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ZARXIO 300 MCG/0.5 ML SYRINGE, is $529.7696 per ML — about 0% below ZARXIO 300 MCG/0.5 ML SYRINGE.
Who manufactures ZARXIO 300 MCG/0.5 ML SYRINGE?
ZARXIO 300 MCG/0.5 ML SYRINGE (NDC 61314031801) is labeled by Sandoz Inc., and CMS classifies it as a brand biologic product.